Patients with a higher density of tumor-infiltrating CD8+ T cells exhibited improved ORR (83.3% vs. 18.2%, p = 0.003), OS (17.17 vs. 10.07 months, p = 0.005) and intrahepatic PFS (13.90 vs. 6.67 months, p < 0.001; Figures 7C–E). The gene discussed is CD8A; the disease is neoplasm.